FDA’s Botched Review of Moderna’s Flu mRNA Vaccine
FDA’s Botched Review of Moderna’s Flu mRNA Vaccine by Maryanne Demasi at Brownstone Institute When the FDA licensed Moderna’s new mRNA flu vaccine last week, legacy media coverage focused almost exclusively on efficacy. The pivotal trial reported that the vaccine was “26.6% more effective” than a conventional flu vaccine at preventing protocol-defined influenza-like illness. What received far less scrutiny was a much more serious problem in the trial data published in The New England Journal of Medicine—much of it relegated to an appendix behind a paywall. An analysis of that appendix…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.